Class I recall: a different drug (ranitidine) found in cetirizine allergy tablets — traced from patient complaints of red spots (JB Chemicals)
Customers reported discolored tablets with red dots on cetirizine hydrochloride tablets 5 mg, and investigation determined the material to be ranitidine. Classified Class I as cross contamination with other products, covering 34,020 bottles of 100 distributed nationwide.
Recall overview (primary data)
- ClassificationClass I (most serious)
- Product typeDrug
- Recalling firmJB Chemicals and Pharmaceuticals Ltd
- ReasonCross Contamination with Other Products: Customer complaints for appearance of discolored tablets and red dots observed on Cetirizine Hydrochloride Tablets USP 5 mg. Determined to be Ranitidine.
- DistributionNationwide in the USA
- Recall initiated2026-06-24
Key points
- The product is cetirizine hydrochloride tablets USP 5 mg in 100-count bottles — 34,020 bottles distributed nationwide.
- The recall reason is cross contamination with other products; the material found was ranitidine, a drug that suppresses stomach acid.
- The finding started with customer complaints of discolored tablets and red dots, not with in-house testing.
- Manufactured by Unique Pharmaceuticals Labs, a division of J.B. Chemicals and Pharmaceuticals in Mumbai, and distributed by Rising Pharma Holdings.
- Of the 1,408 recall records this site holds as of 2026-08-28, only 2 cite cross contamination as the reason.
1When one drug turns up inside another
Recall reasons for medicines fall into several families: the amount of active ingredient is wrong, an impurity exceeds its limit, foreign matter got in. This one belongs to none of them. An entirely different medicine was present. Cetirizine is an antihistamine used for conditions such as hay fever; ranitidine, the material found, suppresses stomach acid.
For two drugs with different uses and different actions to share a bottle means that powder or particles crossed somewhere in the changeover or cleaning of a production line.
2The discovery started with customer complaints
What the record states plainly is that this began not with in-house testing but with complaints from people using the product. What was reported was visible: discolored tablets, red dots. Quality control is meant to catch problems before shipping, and here it did not; the finding came after the product reached people.
Put the other way, this was a form of contamination that left a visible trace, which is how it came to light at all. Contamination that shows in neither color nor shape has no guarantee of being noticed the same way.
3Cross contamination appears in 2 of 1,408 records
Sorting the 1,408 FDA recall records this site holds as of 2026-08-28 by the wording of their reasons, only 2 cite cross contamination. For comparison, 353 mention sterility or microbial contamination, 105 undeclared allergens, and 39 particulate matter — an order of magnitude apart.
One product mixing into another on a production line is rare, and correspondingly heavy when it happens, which is reflected in the Class I designation here. At which step the contamination occurred, and whether other products are affected, are not part of this record.
Why it matters
One drug appearing inside another is infrequent, but because the substance itself is unintended it differs in kind from a dosage deviation or an impurity. Here a visible change let users notice; contamination that leaves no trace in color or shape has no guarantee of surfacing the same way. Records of line changeover and cleaning become the only handle once product has shipped.
FAQ
How do cetirizine and ranitidine differ?
Why did customer complaints find it?
Is cross contamination common?
Sources (primary)
Source: openFDA (U.S. FDA, CC0 public domain). Data is provided as-is and must not be used for medical decisions. Verify the latest and exact details with the official FDA recall information. This site is not endorsed or certified by the U.S. FDA.
- FDA recall information (official)
- openFDA (data provider)
- Recall number: D-0732-2026